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Abstract. Reductions in malaria morbidity have been reported following azithromycin mass drug administration (MDA) for
trachoma. The recent Macrolides Oraux pour Reduire les Deces avec un Oeil sur la Resistance (MORDOR) trial reported a
reduction inchildmortality followingbiannualazithromycinMDA.Here,we investigate theeffectsofazithromycinMDAonmalaria
at the MORDOR-Malawi study site. A cluster-randomized double-blind placebo-controlled trial, with 15 clusters per arm, was
conducted.House-to-housecensuswasupdatedbiannually,andazithromycinorplacebosyrupwasdistributedtochildrenaged
1–59months for a total of four biannual distributions. At baseline, 12-month, and 24-month follow-up visits, a randomsample of
1,200childrenwasassessed formalariawith thickand thinbloodsmears andhemoglobinmeasurement. In thecommunity-level
analysis, therewasnodifference in theprevalenceofparasitemia (1.0%lower inazithromycin-treatedcommunities;95%CI:−8.2
to 6.1), gametocytemia (0.7% lower in azithromycin-treated communities; 95% CI: −2.8 to 1.5), or anemia (1.7% lower in
azithromycin-treatedcommunities;95%CI:−8.1to4.6)betweenplaceboandazithromycincommunities.Further interrogationof
the data at the individual level, both per-protocol (including only those who received treatment 6 months previously) and by
intention-to-treat, did not identify differences in parasitemia between treatment arms. In contrast to several previous reports, this
study did not show an effect of azithromycin MDA on malaria parasitemia at the community or individual levels.
INTRODUCTION
TheMacrolides Oraux pour Reduire les Deces avec un Oeil sur
la Resistance (MORDOR) trial, conducted in Niger, Malawi, and
Tanzania, demonstrated a reduction in child mortality following
biannual mass drug administration (MDA) with azithromycin.1
The mechanism through which such a reduction in child mor-
tality may occur is not clear. Azithromycin is a broad spectrum
antibiotic with a relatively long half-life which is used in the
treatment of pneumonia and diarrhea but also displays anti-
malarial activity.2,3 Field trials of the effects of azithromycin
MDA on malaria infection and symptoms have previously re-
ported reductions in malariometric indices; and recent results
from the Niger MORDOR site indicate an association between
azithromycin MDA and lower parasitemia.3–7 It is feasible that
the mortality benefit seen with azithromycin MDA may be due,
at least in part, to a decrease in malaria prevalence or severity.
This study reports malaria parasitemia, parasite density,
and gametocytemia data from the MORDOR Malawi study
site, aiming to improve our understanding of the effects of
azithromycin MDA on malaria infection. Samples were col-
lected from children in villages representative of theMORDOR
trial and used the same biannual census updates and cluster-
randomized trial structure to make the results as representa-
tive as possible of the wider study area and to assess
community-level effects of any outcomes. The hypothesis for
this study was that azithromycin MDA would reduce the
community prevalence of malaria compared with placebo.
METHODS
Trial design. The randomization unit for the MORDOR trial
in Malawi was defined as the catchment area of a health
surveillance assistant (HSA), approximately 1,000 total pop-
ulation. Communities with a population < 200 or > 2,000 on a
pre-baseline census were excluded. Thirty communities were
randomly selected from the pool of communities for the
MORDOR trial for follow-up as part of this malaria prevalence
study. The randomization was stratified to produce six com-
munities in each of the five geographical zones of Mangochi
district for geographical generalizability and for logistical
reasons regarding fieldwork. Biannual census updates were
performed, and communities received study drug in the same
treatment rounds as the MORDOR trial.
Participants. All children aged 1–59 months and weighing
³ 3.8 kg were eligible for treatment at each of four biannual
mass distributions. At the baseline, 12-month, and 24-month
follow-up visits, guardians of a randomly selected sample of
40 children per community were asked to provide written in-
formed consent for finger-prick blood samples. The proce-
dures and study were explained by trained local nursing staff
who subsequently collected thick and thin blood smears if
consent was obtained. Illiterate guardians provided a thumb
print to acknowledge consent.
Interventions. Azithromycin was administered at a dose of
20 mg/kg. Children old enough to stand received an approx-
imate dose estimated from their height, and younger children
were weighed. The placebo bottles and suspension appeared
identical to azithromycin. Distribution of drug took place after
sample collection was complete and was performed by the
HSAs and field-workers conducting house-to-house visits.
Guardians were asked to inform the HSA of any adverse
events that occurred within 7 days of receiving study drug.
Health surveillance assistants subsequently informed the
study team.
Outcomes. The primary prespecified outcome was preva-
lence of malaria parasites on thick blood smears in children
aged 1–59 months. Prespecified secondary outcomes in-
cluded parasite density, gametocyte prevalence and density,
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hemoglobin concentration, and presence of anemia (Hb < 11
g/dL). Primary analyses were by intention-to-treat, and per-
protocol analyses were secondary.
Samplecollection.Sample collection tookplaceduring the
baseline visit (May–July 2015) and at 12-month and 24-month
visits (April–June 2016 and 2017, respectively), approximately
6 months after the second and fourth treatment rounds.
Sample collection involved selected children receiving a finger
stick and thick and thin blood smears collected on a single
slide (hemoglobin measurement was performed using a
Hemocue 201 device (Ängelholm, Sweden)). Slides were la-
beled with a random number and barcode and scanned using
the data collection app to link to census data. The thin smear
was fixed with absolute methanol and the slide stained with
8% Giemsa. Parasite density was assessed from the thick
smear by two independent slide readers at MORDOR trial
laboratories in Mangochi and Blantyre. Parasite density was
estimated as parasites per microliter by assessing up to 100
high-power fields and assuming that 500 high-power fields
contain the equivalent of one microliter of blood. If after two
reads there was a discrepancy of greater than 20%, a third
reading was taken as the final read. Thin slides were used to
assess malaria species.
Sample size. Fifteen communities per arm, with 40 children
sampled from each community (600 children per arm), pro-
vided 90%power to detect a reduction of malaria parasitemia
from 20% to half that value at each study phase.
Randomization and blinding. Study drug was labeled with
six letters by themanufacturer (Pfizer Inc., NewYork, NY), with
three letters corresponding to azithromycin and three to pla-
cebo. Communities were randomly assigned to one of the six
drug letters by the study statistician using the statistical
package R (R Foundation for Statistical Computing, Vienna,
Austria). All field and laboratory staff and participants in
Malawi were blinded to the treatment code until after all data
collection was complete.
Statistical methods. The main analysis was by intention-
to-treat at the community level, in keeping with the cluster-
randomized design of the MORDOR trial. Further analyses by
both intention-to-treat and per-protocol at the individual level
were used to further explore the data.
Community-level prevalence of parasitemia, anemia, and
gametocytemia by treatment arm were assessed for the 12-
month and 24-month visits using mixed-effects linear
regression models including fixed effects for baseline preva-
lence and study phase and a random effect for community.
Individual-level parasitemia, parasite density, hemoglobin,
and gametocytemia by treatment arm were assessed for the
12-month and 24-month visits using mixed-effects logistic or
linear regression models, as appropriate, including fixed ef-
fects for age, baseline prevalence, and study phase and
nested random effects for individuals within communities.
Individual-level analyseswereperformedbyboth intention-to-
treat and per-protocol, including only those who received
study drug as indicated at the previous phase. Intra-class
correlation coefficients (ICCs) were derived from the re-
gression models at the level of the randomization unit.
The hemoglobin levels in individuals between the treatment
arms were split by the presence of parasitemia and compared
using Student’s t-test. Association between the presence of
parasitemia and the hemoglobin level was assessed at the
individual level using Student’s t-test.
Ethical approval. Ethical approval for morbidity assess-
ments alongside the MORDOR trial was obtained from the
College of Medicine, University of Malawi; the London School
of Hygiene and Tropical Medicine; and the UCSF Committee
on Human Research. Written consent was obtained from the
guardians of participants. There were no incentives for
participation.
RESULTS
Demographic details of sampled children in the 30 study
communities are shown in Table 1. Age and gender distributions
of sampled children were similar between the azithromycin-
and placebo-treated communities. Study drug was distrib-
uted in all 30 communities at each round, with 76.6% of
eligible children treated in azithromycin communities over all
phases and 73.5% in placebo communities. The trial flow is
shown in Figure 1, including the number of malaria blood films
taken. No serious adverse events attributable to study drug
were reported.
Over 98% of malaria species detected were Plasmodium
falciparum, and the remainder were Plasmodium malariae.
Analyses included bothmalaria species. The community-level
prevalence of malaria parasitemia, anemia, and game-
tocytemia was similar between placebo and azithromycin
groups at baseline (unadjusted data shown in Table 2).Malaria
parasitemia did not change significantly between treatment
groups at the 12- and 24-month follow-up rounds: 1.0% lower
in azithromycin-treated communities after adjusting for
baseline parasitemia and follow-up phase (95% CI: −8.2
to 6.1%, P = 0.78; ICC = 0.51). The prevalence of anemia,
defined as Hb < 11 g/dL, was not significantly different be-
tween treatment groups at the 12- and 24-month follow-up
visits: 1.7% lower in azithromycin-treated communities (95%
CI: −8.1 to 4.6%, P = 0.59; ICC = 0.09). The prevalence of
gametocytemia also remained similar between treatment
groups at the follow-up rounds: 0.7% lower in azithromycin-
treated communities (95% CI: −2.8 to 1.5%, P = 0.53;
ICC < 0.01).
Individual-level unadjusted data are shown by intention-to-
treat in Table 3 and per-protocol in Table 4. The prevalence of
parasitemia, parasite density, and hemoglobin was similar at
baseline. By intention-to-treat, parasitemia was not signifi-
cantly different between treatment groups at the 12- and
24-month follow-up visits: the odds ratio for individuals in
azithromycin- compared with placebo-treated communities
after adjusting for age, baseline parasitemia, and follow-up
phase was 0.89 (95% CI: 0.53 to 1.50, P = 0.67; ICC = 0.06).
TABLE 1
Characteristics of children sampled in the study communities at the
start of each follow-up period
Placebo N (%) Azithromycin N (%)
Age distribution (months)
1–11 259 (47.9) 282 (52.1)
12–23 385 (51.2) 367 (48.8)
24–35 362 (50.2) 359 (49.8)
36–47 351 (51.1) 336 (48.9)
48–59 324 (50.2) 321 (49.8)
Gender
Female 878 (50.3) 866 (49.7)
Male 841 (50.4) 828 (49.6)
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Parasite density in parasitemic individuals was similar be-
tween treatment groups at the 12- and 24-month follow-up
visits: 23 parasites/μL lower in individuals in azithromycin-
treated communities after adjusting for age, baseline para-
sitemia, and follow-up phase (95%CI: −67 to 22 parasites/μL,
P = 0.32; ICC = 0.02). Hemoglobin was also similar between
treatment groupsat 12- and24-month follow-upvisits: 0.08g/dL
lower in individuals in azithromycin-treated communities
after adjusting for age, baseline community prevalence of
anemia, and follow-up phase (95% CI: −0.36 to 0.19, P =
0.56; ICC = 0.05).
In theper-protocol analysis, the odds ratio for parasitemia in
azithromycin- compared with placebo-treated individuals at
12- and 24-month visits after adjusting for age, baseline par-
asitemia, and follow-up phasewas 0.71 (95%CI: 0.43 to 1.16,
P = 0.17; ICC = 0.06). Parasite density in parasitemic indi-
viduals was similar between treatment groups at 12- and
24-month visits after adjusting for age, baseline parasitemia,
FIGURE 1. Trial flow. Communities were randomly selected from the same pool as the main MORDORmortality study. Individuals could join the
cohort at each of the biannual follow-up censuses.
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and follow-up phase: 19 parasites/μL lower in azithromycin-
treated individuals (95% CI: −45 to 8, P = 0.17; ICC = 0.03).
Hemoglobin levels were also similar between treatment groups
at the 12- and 24-month follow-up visits after adjusting for age,
baseline community prevalence of anemia, and follow-up
phase: 0.03 g/dL lower in azithromycin-treated individuals
(95%CI: −0.32 to 0.25,P = 0.81; ICC = 0.04), shown in Table 4.
Therewere no significant differences in gametocyte prevalence
or gametocytedensity in gametocyte-positive individualswhen
analyzed by intention-to-treat or per-protocol, shown in
Supplemental Tables 1 and 2.
In the individual-level per-protocol and intention-to-treat
analyses, there was a positive association between the out-
comes (parasitemia and hemoglobin) and both age and
baseline community parasitemia or hemoglobin. The effect of
treatment did not vary with age when an interaction term be-
tween the treatment arm and age was included in the models.
Hemoglobin levels were approximately 1 g/dL lower in
parasitemic individuals at all study phases and in azithromycin
and placebo groups, shown in Supplemental Table 3.
DISCUSSION
Several morbidity sub-studies were nested within the
MORDOR trial to investigate mechanisms through which
azithromycin MDA may reduce mortality. This research was
not carried out in the MORDOR mortality study communities
to reduce the risk of interventions impacting the primary
MORDORoutcome ofmortality. Morbidity study communities
were randomly selected from the same pool as the main
MORDOR trial, designed so that results would be represen-
tative of the mortality study. This malaria study, nested within
MORDOR, did not identify a reduction in malaria parasitemia,
gametocytemia, or hemoglobin in azithromycin-treated
compared with placebo-treated communities. Secondary
analyses at the individual level, by intention-to-treat and per-
protocol, including only those who received study drug at the
previous phase, approximately 6 months earlier, also did not
identify significant differences in theprevalenceof parasitemia
or parasite density in parasitemic individuals.
Previous published reports of the effect of azithromycin
MDA on malaria have suggested a reduction in malaria over
6-month duration.4,5,7 The mechanism through which a re-
duction in parasitemia over this time period may occur is
unclear. Azithromycin displays delayed activity against the
malaria parasite, preventing the progeny of antibiotic-treated
parasites from fully maturing, and has a long terminal half-life
of approximately 68 hours. These are properties that could
feasibly contribute to a period of antimalarial activity of days to
weeks but not months.8 The studies showing longer term ef-
fects were in Niger and the Gambia, in areas with lower
background levels of parasitemia, which may be more
amenable to reductions in transmission that could last longer
than individual-level prophylaxis and treatment. This study
assessedmalaria gametocytemia as an effect of azithromycin
on the sexual stages of the parasite which could explain the
longer term community-level reductions in parasitemia as
previously reported. Reductions in gametocytemia were not
identified, which is consistent with previous evidence.9
In the context of the MORDOR trial showing a reduction in
child mortality, this study does not provide evidence for an
effect of azithromycin MDA on malaria mortality at the Malawi
site.1 The best estimates for the odds ratio for the presence of
parasitemia in individuals in azithromycin communities com-
pared with placebo ones were 0.89 by intention-to-treat and
0.71 per-protocol, and it is possible that this study of limited
size with follow-up restricted to 6 months post-MDA repre-
sents type II error. However, while the main MORDOR trial
suggested increased child survival benefit in those younger
than 6 months, in this study, age and parasitemia were posi-
tively associated (i.e., lower parasitemia in infants), further
suggesting that the child survival benefits in MORDOR were
not best explained through effects on malaria. Further in-
vestigation of the effects of azithromycin MDA on malaria
severity and mortality, as well as cause-specific mortality for
all the major causes of child mortality, is required to improve
our understanding of whether the reported mortality reduc-
tions may be due to specific anti-pathogen effects or to other
mechanisms, such as the immunomodulatory and anti-
inflammatory effects of azithromycin.10,11
The prevalence of malaria parasitemia in this study was
approximately 30% in children aged 1–59 months. Malawi is
hyperendemic for malaria with 95% of the population sus-
ceptible to infection, and large-scale surveys before and after
this study reported malaria parasitemia prevalence of 33%
and 24%, respectively.12,13 Malaria was also the commonest
inferred cause of death from verbal autopsy in the MORDOR
trial in Malawi.14 Parasitemic children had significantly lower
mean hemoglobin levels at all follow-up rounds, consistent
with known effects of malaria as a cause of anemia in
children.15–17 This analysis provides some validation of the
integrity of the data. In addition, the ICCs were low for all
analyses, suggesting considerable heterogeneity in malaria
infection and hemoglobin levels by community, consistent
with usual epidemiological patterns of malaria and similar to
the MORDOR Niger site data.7
One limitationof this study is that treatment tookplaceat the
beginning and end of each dry season for logistical reasons.
Mathematical modeling of the effect of azithromycin MDA on
malaria in areas of highly seasonal transmission suggests
there may be most benefit from treatment during the low-
transmission season when treatment of established infection
may producemore sustained benefit because of the lower risk
of reinfection.18 At the community level, this may also reduce
TABLE 2
Community level prevalence of malaria parasitemia, anemia (Hb < 11 g/dL), and gametocytemia in the 30 study communities by treatment arm
(unadjusted)
Mean prevalence of parasitemia (95% CI) Mean prevalence of anemia (95% CI) Mean prevalence of gametocytemia (95% CI)
Study phase Placebo Azithromycin Placebo Azithromycin Placebo Azithromycin
Baseline 29.2% (18.8–39.6%) 31.8% (21.8–41.8%) 58.1% (50.8–65.4%) 57.2% (50.1–64.2%) 6.2% (3.4–9.0%) 8.0% (4.3–11.7%)
12 months 34.8% (25.9–43.8%) 37.3% (27.7–47.0%) 59.2% (52.5–65.9%) 56.4% (49.7–63.2%) 5.0% (1.8–8.0%) 4.7% (2.3–7.1%)
24 months 29.2% (21.6–36.9%) 27.8% (18.6–37.0%) 51.7% (41.9–61.4%) 50.2% (43.5–56.8%) 3.5% (1.6–5.4%) 3.3% (0.6–6.1%)



















































































































































































































































































































































































































































































































































































































































































































































































































































































































the reservoir of infectious individuals at the beginning of the
following high-transmission period. In Malawi, where despite
some seasonality, malaria prevalence remains high year-
round, the optimal time to treat, if indeed there is any benefit
from the intervention, is unclear.
Monitoring for infection took place during the baseline,
12-month, and 24-month visits, early in the dry season, and
approximately 6months after the previous treatment round for
the latter two visits. This seasonality and timing of sample
collection may not provide a complete understanding of the
effect of the biannual azithromycin MDA on malaria preva-
lence, which may vary with time lapsed after administration.
Finally, while carefully designed to be representative of the
MORDOR trial site in Malawi, the data may not be represen-
tative of other countries with different malaria prevalence and
healthcare interventions, although some data are available
from other MORDOR sites.7 Any effect of azithromycin MDA
on malaria may be impacted by other malaria interventions,
such as seasonal malaria chemoprophylaxis (SMC), which
was not taking place at the MORDOR-Malawi site. A recent
study indicated no additional child mortality benefit when
adding azithromycinMDA to SMC inMali and Burkina Faso.19
In conclusion, a cluster-randomized placebo-controlled
study of the effects of azithromycin MDA on malaria para-
sitemia was unable to detect a difference in malaria para-
sitemia at the community or individual levels, providing no
evidence that any child survival benefit was mediated by ef-
fects on malaria mortality. Further investigation is required to
understand the effect of azithromycin MDA on malaria mor-
bidity and mortality and, indeed, to elucidate the mechanisms
by which azithromycin MDA may reduce child mortality.
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